- Home
- CELH vs ASND Comparison
CELH vs ASND Comparison
Compare CELH & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELH
- ASND
- Stock Information
- Founded
- CELH 2004
- ASND 2006
- Country
- CELH United States
- ASND Denmark
- Employees
- CELH N/A
- ASND N/A
- Industry
- CELH Beverages (Production/Distribution)
- ASND Biotechnology: Pharmaceutical Preparations
- Sector
- CELH Consumer Staples
- ASND Health Care
- Exchange
- CELH Nasdaq
- ASND Nasdaq
- Market Cap
- CELH 15.3B
- ASND 12.2B
- IPO Year
- CELH N/A
- ASND 2015
- Fundamental
- Price
- CELH $41.52
- ASND $197.74
- Analyst Decision
- CELH Strong Buy
- ASND Strong Buy
- Analyst Count
- CELH 18
- ASND 17
- Target Price
- CELH $62.39
- ASND $245.76
- AVG Volume (30 Days)
- CELH 6.5M
- ASND 377.7K
- Earning Date
- CELH 11-06-2025
- ASND 11-12-2025
- Dividend Yield
- CELH N/A
- ASND N/A
- EPS Growth
- CELH N/A
- ASND N/A
- EPS
- CELH 0.13
- ASND N/A
- Revenue
- CELH $2,125,838,000.00
- ASND $576,332,355.00
- Revenue This Year
- CELH $85.38
- ASND $104.98
- Revenue Next Year
- CELH $31.08
- ASND $79.91
- P/E Ratio
- CELH $343.59
- ASND N/A
- Revenue Growth
- CELH 55.07
- ASND 54.50
- 52 Week Low
- CELH $21.10
- ASND $118.03
- 52 Week High
- CELH $66.74
- ASND $216.45
- Technical
- Relative Strength Index (RSI)
- CELH 18.19
- ASND 46.23
- Support Level
- CELH $56.96
- ASND $195.80
- Resistance Level
- CELH $61.49
- ASND $202.41
- Average True Range (ATR)
- CELH 2.71
- ASND 6.49
- MACD
- CELH -2.25
- ASND -0.96
- Stochastic Oscillator
- CELH 4.35
- ASND 30.85
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.